Authorization

Pomerantz Law Firm Announces the Filing of a Class Action against STAAR Surgical Company and Certain Officers - STAA

NEW YORK, Sept. 7, 2020 /PRNewswire/ --APomerantz LLP announces that a class action lawsuit has been filed against STAAR Surgical Company A("STAAR" or the "Company") (NASDAQ: STAA) and certain of its officers.AA The class action, filed in United States District Court for the Central District of California, Southern Division, and docketed under 20-cv-01660, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquiredASTAAR Surgical Company securities between February 26, 2020, and August 10, 2020, inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder by the SEC, 17 C.F.R. A 240.10b-5.If you are a shareholder who purchased STAAR securities during the class period, you have until October 19, 2020, to ask the Court to appoint you as Lead Plaintiff for the class.A A copy of the Complaint can be obtained at www.pomerantzlaw.com. A To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.comAor 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.A [Click here for information about joining the class action]ASTARR designs, develops, manufactures, and sells implantable lenses for the eye and companion delivery systems used to deliver the lenses into the eye.A STAAR's primary products are: (1) "implantable CollamerA lenses," or "ICLs," used in refractive surgery; and (2) intraocular lenses, or "IOLs," used in cataract surgery.The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts to investors. Specifically, Defendants misrepresented and/or failed to disclose to investors that the Company was overstating and/or mischaracterizing: (1) its sales and growth in China; (2) its marketing spend; (3) its research and development expenses; and that as a result of the foregoing, (4) Defendants' public statements were materially false and misleading at all relevant times.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«     2020    »
 123456
78910111213
14151617181920
21222324252627
28293031